Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Dose Escalation Data from transcendIT-101 Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors Presented

November 16, 2022

Onivyde® Regimen Demonstrated Statistically Significant Improvement In Overall Survival In Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

November 16, 2022

FAILED TRIAL: Ph 3 DREAMM-3 trial of Blenrep (belantamab mafodotin) in patients with RRMM did not meet primary endpoint of progression-free survival (PFS)

November 16, 2022

Interim Analysis of Ph 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2) provided

November 16, 2022

COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients

November 16, 2022

Positive 1-Year and 2-Year OS Data for Patients with R/R AML in Ph 1 Actimab-A CLAG-M Combo Trial Announced

November 16, 2022

Initial Results From Ph 2 Trial Demonstrate Potential Of Trilaciclib To Reduce Adverse Events Related To An ADC

November 16, 2022

Promising Initial Dose-Escalation Results from Ph 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors announced

November 16, 2022

Promising SRF388 Monotherapy Data in NSCLC announced, Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort

November 16, 2022

Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Ph 2 trial in advanced ER-positive breast cancer

November 4, 2022

Capivasertib plus Faslodex significantly improved PFS vs. Faslodex in CAPItello-291 Ph 3 trial

November 4, 2022

Initial Dose-Escalation Results from the First-in-Human Ph 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors

November 4, 2022

Updated Findings from the Ph 2 SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC Presented

November 4, 2022

FAILED TRIAL: Ph 2 AMEERA-3 trial of amcenestrant in ER+/HER2- advanced or metastatic breast cancer did not meet primary endpoint of improving PFS

November 4, 2022

Preliminary Ph 1 Clinical Data from ARROS-1 Trial of NVL-520 for Patients with ROS1-Positive NSCLC reported

November 4, 2022

Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer presented

November 2, 2022

Findings from First-in-Human Study of CBX-12 presented

November 2, 2022

Data from CheckMate -76K Shows that Opdivo Reduced the Risk of Recurrence or Death by 58% vs. Placebo in Patients with Completely Resected Stage IIB/C Melanoma

October 26, 2022

LuMIERE Ph 1 Data Of FAP-2286 announced

October 26, 2022

Positive Topline Results Announced from Final PFS Analysis of BRUKINSA vs IMBRUVICA in Ph 3 ALPINE trial in CLL patients

October 19, 2022

TRITON3 Ph 3 Trial Of Rubraca Achieves Primary Endpoint In Men With mCRPC With BRCA Or ATM Mutations

October 12, 2022

Ph 3 TALAPRO-2 study of TALZENNA® + XTANDI® in mCRPC patients met its primary endpoint of rPFS compared with placebo plus XTANDI

October 12, 2022

PERLA Ph 2 trial Of Jemperli (Dostarlimab) + Chemotherapy In Patients With mNSCLC met the primary endpoint of ORR

October 12, 2022

Results Of IDMC Review Of 12 Week Safety Data From ENVASARC Ph 2 Pivotal Trial announced – Trial To Proceed As Planned

October 12, 2022

New Long-Term Data from L-MIND Shows Durable Response to Monjuvi® (tafasitamab-cxix) for R/R DLBCL Patients

October 5, 2022
Page1 … Page26 Page27 Page28 Page29 Page30

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.